Wei Yongbao, Hong Huaishan, Huang Haijian
Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.
Department of Urology, Fujian Provincial Hospital, Fuzhou, Fujian, China.
Front Oncol. 2023 Mar 9;13:1118222. doi: 10.3389/fonc.2023.1118222. eCollection 2023.
Langerhans cell sarcoma (LCS) is a rare malignancy of dendritic cells and usually results in a poor oncological outcome. Thus, LCS is usually given a positive administration. Herein, we presented the first case of primary LCS in the urinary bladder staged T1N0M0 and treated by TURBT and short-term local chemotherapy. Our experience in this unique case may suggest that LCS in the urinary bladder with a non-muscle-invasive stage may be managed according to the treatment model of non-muscle-invasive urothelial carcinoma of the urinary bladder.
朗格汉斯细胞肉瘤(LCS)是一种罕见的树突状细胞恶性肿瘤,通常导致不良的肿瘤学预后。因此,LCS通常给予积极治疗。在此,我们报告了首例膀胱原发性LCS,分期为T1N0M0,采用经尿道膀胱肿瘤电切术(TURBT)和短期局部化疗进行治疗。我们在这个独特病例中的经验可能表明,处于非肌层浸润期的膀胱LCS可根据膀胱非肌层浸润性尿路上皮癌的治疗模式进行处理。